EPS von Shenzhen Chipscreen Biosciences Co., Ltd. ist -0.19
Der Gewinn pro Aktie (EPS) ist der Anteil des Gewinns eines Unternehmens, der jeder im Umlauf befindlichen Stammaktie zugewiesen wird. Es wird der Verdünnung angepasst und über letzten zwölf Monate nachgerechnet.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.